Q2 EPS Forecast for Corbus Pharmaceuticals Cut by Analyst

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at Wedbush reduced their Q2 2025 earnings estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst R. Driscoll now forecasts that the biopharmaceutical company will earn ($1.03) per share for the quarter, down from their previous forecast of ($0.76). Wedbush has a “Outperform” rating and a $51.00 price target on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. Wedbush also issued estimates for Corbus Pharmaceuticals’ Q3 2025 earnings at ($1.14) EPS, Q4 2025 earnings at ($0.90) EPS, FY2025 earnings at ($4.38) EPS, FY2026 earnings at ($4.02) EPS, FY2027 earnings at ($6.55) EPS and FY2028 earnings at ($5.28) EPS.

Other research analysts also recently issued research reports about the stock. B. Riley restated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Wednesday. Royal Bank of Canada dropped their price target on shares of Corbus Pharmaceuticals from $65.00 to $58.00 and set an “outperform” rating on the stock in a research report on Wednesday. HC Wainwright decreased their price objective on Corbus Pharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday. StockNews.com upgraded Corbus Pharmaceuticals to a “sell” rating in a report on Thursday, March 6th. Finally, Oppenheimer decreased their price target on Corbus Pharmaceuticals from $60.00 to $56.00 and set an “outperform” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $50.88.

Corbus Pharmaceuticals Stock Down 3.0 %

Shares of CRBP opened at $6.45 on Friday. The business’s fifty day moving average is $6.33 and its 200 day moving average is $10.81. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $61.90. The stock has a market cap of $78.90 million, a P/E ratio of -1.38 and a beta of 3.19.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.13).

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC boosted its holdings in shares of Corbus Pharmaceuticals by 28.5% in the 4th quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company’s stock worth $13,833,000 after buying an additional 259,735 shares during the last quarter. Millennium Management LLC raised its position in Corbus Pharmaceuticals by 215.0% in the fourth quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company’s stock worth $4,563,000 after acquiring an additional 263,902 shares during the period. Altium Capital Management LLC grew its position in shares of Corbus Pharmaceuticals by 97.4% during the 4th quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company’s stock valued at $4,543,000 after acquiring an additional 190,000 shares during the period. Prosight Management LP increased its stake in shares of Corbus Pharmaceuticals by 107.7% during the 4th quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company’s stock worth $3,186,000 after purchasing an additional 140,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Corbus Pharmaceuticals by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 263,532 shares of the biopharmaceutical company’s stock worth $3,110,000 after purchasing an additional 13,773 shares during the period. Institutional investors own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.